Drug intelligence / Profile preview

FREE008

Development stage: Preclinical
Lead developer: Freedom Biosciences
Modality: Small Molecules

Overview

**FREE008** is an investigational neuropsychiatric combination-drug program developed by Freedom Biosciences for **major depressive disorder**. Freedom Biosciences described it as a non-hallucinogenic psilocybin program expected to enter a UK Phase 1 study in 2025; a later industry pipeline tracker identifies the program as a combination of psilocybin and an undisclosed phosphodiesterase 9 inhibitor. ([youtube.com](https://www.youtube.com/watch?v=Pd1whzFX26A))

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on FREE008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FREE008.

Explore the full profile